123 related articles for article (PubMed ID: 21248172)
1. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
Dasanu CA
J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
[TBL] [Abstract][Full Text] [Related]
2. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.
Aldinucci D; Gloghini A; Pinto A; De Filippi R; Carbone A
J Pathol; 2010 Jul; 221(3):248-63. PubMed ID: 20527019
[TBL] [Abstract][Full Text] [Related]
3. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma.
Gupta S; Yeh S; Chami R; Punnett A; Chung C
Eur J Cancer; 2013 Oct; 49(15):3255-61. PubMed ID: 23791542
[TBL] [Abstract][Full Text] [Related]
5. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.
Yurchenko M; Sidorenko SP
Exp Oncol; 2010 Dec; 32(4):214-23. PubMed ID: 21270747
[TBL] [Abstract][Full Text] [Related]
7. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
8. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
9. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
Ishida T; Ishii T; Inagaki A; Yano H; Kusumoto S; Ri M; Komatsu H; Iida S; Inagaki H; Ueda R
Leukemia; 2006 Dec; 20(12):2162-8. PubMed ID: 17039235
[TBL] [Abstract][Full Text] [Related]
10. Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30).
Sarker AB; Akagi T; Jeon HJ; Miyake K; Murakami I; Yoshino T; Takahashi K; Nose S
Am J Pathol; 1992 Jul; 141(1):19-23. PubMed ID: 1352944
[TBL] [Abstract][Full Text] [Related]
11. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells.
Hsu PL; Hsu SM
Cancer Res; 1990 Jan; 50(2):350-7. PubMed ID: 2153049
[TBL] [Abstract][Full Text] [Related]
12. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
[TBL] [Abstract][Full Text] [Related]
13. Immune reactions in classical Hodgkin's lymphoma.
Poppema S; Potters M; Emmens R; Visser L; van den Berg A
Semin Hematol; 1999 Jul; 36(3):253-9. PubMed ID: 10462325
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Schulz H; Engert A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
[TBL] [Abstract][Full Text] [Related]
15. Immunopathology of Hodgkin's disease. Characterization of Reed-Sternberg cells with monoclonal antibodies.
Strauchen JA; Dimitriu-Bona A
Am J Pathol; 1986 May; 123(2):293-300. PubMed ID: 3085509
[TBL] [Abstract][Full Text] [Related]
16. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
17. MMA monoclonal antibody is a superior anti-CD15 reagent for the diagnosis of classical Hodgkin's lymphoma?
Pellegrini W; Bresciani G; De Zorzi A; Marocolo D; Ungari M; Facchetti F
Haematologica; 2007 May; 92(5):708-9. PubMed ID: 17488702
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells.
Hummel M; Ziemann K; Lammert H; Pileri S; Sabattini E; Stein H
N Engl J Med; 1995 Oct; 333(14):901-6. PubMed ID: 7545266
[TBL] [Abstract][Full Text] [Related]
19. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
20. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.
Gerber HP
Biochem Pharmacol; 2010 Jun; 79(11):1544-52. PubMed ID: 20096666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
